ArticlePloS one2017
Nephropathy in Pparg-null mice highlights PPARγ systemic activities in metabolism and in the immune system.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 39 citations in OpenAlex.
- Proinflammatory keratinocytes drive a novel mouse model of autoimmunity with systemic and cutaneous lupus erythematosus.Immunity & inflammation · 2026Article
- The signaling pathway of PPAR-γ and its protective role in various diseases.Caspian journal of internal medicine · 2026Review
- Prognostic Model Construction of Disulfidptosis-Related Genes and Targeted Anticancer Drug Research in Pancreatic Cancer.Molecular biotechnology · 2025Article
- Stromal vascular fraction inhibits renal fibrosis by regulating metabolism and inflammation in obstructive nephropathy.Frontiers in pharmacology · 2025Article
- Roles of pyroptosis and immune infiltration in aortic dissection.Frontiers in molecular biosciences · 2024Article
- PPARG: A Novel Target for Yellow Tea in Kidney Stone Prevention.International journal of molecular sciences · 2023Article
- Exploring the role of Xingren on COVID-19 based on network pharmacology and molecular docking.Journal of food biochemistry · 2022Article
- Signaling pathways of chronic kidney diseases, implications for therapeutics.Signal transduction and targeted therapy · 2022Review
- The Role of Peroxisome Proliferator-Activated Receptors in Kidney Diseases.Frontiers in pharmacology · 2022Review
- An integrated RNA sequencing and network pharmacology approach reveals the molecular mechanism of dapagliflozin in the treatment of diabetic nephropathy.Frontiers in endocrinology · 2022Article
- PPARγ and TGFβ-Major Regulators of Metabolism, Inflammation, and Fibrosis in the Lungs and Kidneys.International journal of molecular sciences · 2021Review
- Nuclear receptors in the kidney during health and disease.Molecular aspects of medicine · 2021Review
- Nuclear receptors in podocyte biology and glomerular disease.Nature reviews. Nephrology · 2021Review
- The role of peroxisome proliferator-activated receptors (PPAR) in immune responses.Metabolism: clinical and experimental · 2021Review
- Genetics and Clinical Characteristics of PPARγ Variant-Induced Diabetes in a Chinese Han Population.Frontiers in endocrinology · 2021Article
- Lack of Adiponectin Drives Hyperosteoclastogenesis in Lipoatrophic Mice.Frontiers in cell and developmental biology · 2021Article
- Establishment and characterization of a canine sebaceous epithelial cell line derived from an eyelid mass.The Journal of veterinary medical science · 2020Article
- Review
- Epigenetic Regulation of Adipogenesis in Development of Metabolic Syndrome.Frontiers in cell and developmental biology · 2020Review
- PPARInternational journal of nephrology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peroxisome proliferator-activated receptor γ (PPARγ) is a ligand-dependent transcription factor involved in many aspects of metabolism, immune response, and development. Total-body deletion of the two Pparg alleles provoked generalized lipoatrophy along with severe type 2 diabetes. Herein, we explore the appearance and development of structural and functional alterations of the kidney, comparing Pparg null-mice to their littermate controls (carrying Pparg floxed alleles). We show that renal hypertrophy and functional alterations with increased glucosuria and albuminuria are already present in 3 weeks-old Pparg null-mice. Renal insufficiency with decreased creatinine clearance progress at 7 weeks of age, with the advance of the type 2 diabetes. At 52 weeks of age, these alterations are accompanied by signs of fibrosis and mesangial expansion. More intriguingly, aged Pparg null-mice concomitantly present an anti-phospholipid syndrome (APS), characterized by the late appearance of microthrombi and a mesangioproliferative pattern of glomerular injury, associated with significant plasmatic levels of anti-β2- glycoprotein1 antibodies and renal deposition of IgG, IgM, and C3. Thus, in line with the role of PPARγ in metabolic homeostasis, Pparg null-mice first represent a potent model for studying the initiation and the development of diabetic nephropathy. Second, and in relation with the important PPARγ activity in inflammation and in immune system, these mice also highlight a new role for PPARγ signaling in the promotion of APS, a syndrome whose pathogenesis is poorly known and whose current treatment is limited to prevention of thrombosis events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.